2_NOI-NIAID-_Cardinal Health.doc
DOC document 29 KB Posted
- Solicitation number
- NOI-NIAID-2205816
About this file
This notice provides details for a sole source procurement by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The agency intends to negotiate with Cardinal Health 414 in Dublin, Ohio to procure 150 units of F-18 FDG radiation in quantities up to 15 mCi for use in PET/CT imaging of marmosets, rabbits, and macaques involved in ABSL3 infection experiments. Cardinal Health has provided this product for past, current, and ongoing research projects, and using a different product risks jeopardizing results. The product must be pharmaceutical grade and approved by the NIH and NIAID committees, and follow Nuclear Regulatory Commission guidelines. Performance will be in Bethesda, Maryland. While this is a sole source procurement justified by 41 U.S.C. 1901(e)(2), any responsible sources able to provide comparable services may submit a capability statement by January 17, 2024 to Calvin Robinson to be considered, with a determination of competition being at the government's discretion.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
PRE-SOLICITATION NOTICE
NOI-NIAID-2205816
NAICS – 325412
This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Cardinal Health 414, Dublin, Ohio to procure a quantity of 150, F-18 FDG UD (up to 15 mCi) Radiation for PET/CT imaging.
The animals that must be imaged during the ABSL3 infection experiments include marmosets, rabbits, and macaques. Cardinal Health has provided F18/FDG for the past, current and ongoing research projects. The laboratory must use the same product or risk jeopardizing and hindering research by varying results. The F18 FDG must be pharmaceutical grade for injection and has been approved for use by the NIH NIAID Animal Care and Committee and must follow the Division of Radiation Safety and the Nuclear Radiation Commission guidelines and regulations.
Place of Performance is Bethesda, MD 20892.
The statutory authority for this sole source requirement is 41 U.S.C. 1901 (e )(2) as implemented by FAR 13.601-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2205816) to Calvin Robinson at Calvin.Robinson@nih.gov by 5:00 pm eastern daylight savings time, January 17, 2024. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
File details come from the government source that posted it. Updated .